Europe Tulathromycin Market

Market Overview

The Europe tulathromycin market size has witnessed significant growth in the past and is expected to grow at a CAGR of 5.0% during the forecast period (2022–2030). The patent in the United States, Europe, Canada, and Australia expires in February 2021. Till 2023, the active component tulathromycin is protected in Japan.

Tulathromycin is an antibiotic that works by inhibiting the growth of bacteria. In veterinary medicine, it is typically administered to treat respiratory conditions in cattle and swine. Tulathromycin is covered by Zoetis' intellectual property rights (IPR), and it is marketed as Draxxin.

The high prevalence of BRD and SRD drives the European tulathromycin market. The entry of generic tulathromycin acts as a restraint on this market. On the other hand, a lucrative opportunity for new entrants in generic tulathromycin acts as an opportunity for the tulathromycin market.

Market Dynamics

Europe Tulathromycin Market Drivers:

High Prevalence of BRD and SRD

BRD is the most common pathology in young and adult animals, affecting 20–25% of calves annually, 10% of which experience growth retardation, and up to 6% die. Swine can also have an SRD prevalence rate of around 20%, with a mortality rate of up to 20% and a risk of sequelae in up to 40% of affected animals. Beyond the effects on animal health, BRD and SRD have a significant financial impact on the farmer because of the reduction in animal growth, the expense of diagnosis and treatment, mortality, and the cost of additional work.

Europe Tulathromycin Market Restraints:

Entry of Generic Tulathromycin

Two generic tulathromycin injectable medicines have just received FDA approval in 2021 for the treatment and management of specific diseases in both cattle and swine. Bovine respiratory disease (BRD) caused by Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis is treated with the generic drugs Macrosyn and Increxxa in beef and non-lactating dairy cattle, suckling calves, dairy calves, and veal calves. Additionally, it's used to treat swine respiratory disease (SRD), which is a condition that affects swine and is brought on by pathogens like Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae.

The approved brand-name drug product Draxxin, first approved in 2005, shares the same active component (tulathromycin) with Macrosyn and Increxxa in the same dose form and concentration. These two generic medications are anticipated to reduce the demand for tulathromycin market in the next few years. By consuming some of the demand for the name-brand Draxxin, the demand for generic medicines will increase more quickly.

Europe Tulathromycin Market Opportunities:

Lucrative Opportunity for New Entrants in Generic Tulathromycin

The formulation of Draxxin, which contains the active component tulathromycin, is protected by patents in the United States, Europe, Canada, Australia, and other important markets. Products containing generic tulathromycin are sold in a few nations, including Colombia, Vietnam, Belarus, Russia, Poland, and Croatia. Marketing permits for products containing generic tulathromycin.

This provides the participants with a lucrative opportunity to enter the industry and take advantage of the growth opportunity, particularly in the United States and Europe. Due to the high end-user spending power and greater reliance on beef and dairy cattle, the U.S. and Europe are the two largest markets for the consumption of antibiotics for BRD and SRD. During the forecast period, we anticipate the arrival of numerous new players in the tulathromycin market in these two areas.

Regional Analysis

The Europe tulathromycin market is segmented based on country: Germany, France, the UK, Italy, Spain, and the Rest of Europe. The rest of Europe dominates the country market and is expected to grow at a CAGR of 4.8% during the forecast period.

An innovative triamilide antibacterial drug called tulathromycin has been given European Union approval for use in treating and preventing swine and bovine respiratory diseases. As of 2019, the European region has 143 million pigs and 77 million cattle. Whereas Spain contributed 22% of the pigs and 9% of the cows in the EU, Germany contributed 18% of the pigs and 15% of the cows, France contributed 9% of the pigs and 24% of the cows in the EU, Denmark contributed 9% of the pigs in the EU, the Netherlands contributed another 8%, and Ireland contributed 9% of the cows in the EU.

Segmental Analysis

The Europe tulathromycin market is segmented based on Animal and Country.

Based on Animal, the market is segmented into Cattle and Swine.

Cattle dominated the market and is expected to register a CAGR of 5.4% over the forecast period. Tulathromycin is effective against Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae, the causative agents of swine respiratory disease (SRD).

Recent Developments

• April 20, 2023: Wisdom Pharmaceutical announced that its new tulathromycin product, Tulathromycin Injection, had been approved by the CFDA. A once-daily injectable medication called tulathromycin injection treats SRD in pigs.